Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) PT at $19.45

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has received a consensus recommendation of “Buy” from the fourteen brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $19.45.

Several research firms have recently weighed in on BCRX. Cowen increased their price objective on BioCryst Pharmaceuticals from $18.00 to $21.00 and gave the company an “outperform” rating in a report on Thursday, June 17th. Piper Sandler increased their price target on BioCryst Pharmaceuticals from $18.00 to $22.00 and gave the stock an “overweight” rating in a report on Thursday, August 5th. Jefferies Financial Group downgraded BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating and set a $19.00 price target for the company. in a report on Friday, August 6th. Cantor Fitzgerald initiated coverage on BioCryst Pharmaceuticals in a report on Tuesday, August 3rd. They set an “overweight” rating and a $21.00 price target for the company. Finally, Royal Bank of Canada increased their price objective on BioCryst Pharmaceuticals from $13.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Friday, August 6th.

In other news, Director George B. Abercrombie sold 5,000 shares of the company’s stock in a transaction on Thursday, July 15th. The stock was sold at an average price of $15.69, for a total value of $78,450.00. Following the completion of the sale, the director now owns 8,000 shares in the company, valued at $125,520. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director George B. Abercrombie sold 74,000 shares of the company’s stock in a transaction on Friday, September 10th. The shares were sold at an average price of $15.09, for a total value of $1,116,660.00. The disclosure for this sale can be found here. Corporate insiders own 4.80% of the company’s stock.

A number of hedge funds have recently modified their holdings of BCRX. FMR LLC boosted its stake in BioCryst Pharmaceuticals by 15.9% during the 1st quarter. FMR LLC now owns 3,467,998 shares of the biotechnology company’s stock valued at $28,229,000 after purchasing an additional 475,989 shares during the period. State of New Jersey Common Pension Fund D bought a new stake in BioCryst Pharmaceuticals during the 1st quarter valued at approximately $1,017,000. US Bancorp DE raised its holdings in BioCryst Pharmaceuticals by 470.0% in the 1st quarter. US Bancorp DE now owns 11,400 shares of the biotechnology company’s stock valued at $116,000 after acquiring an additional 9,400 shares in the last quarter. Commonwealth Equity Services LLC raised its holdings in BioCryst Pharmaceuticals by 4.2% in the 1st quarter. Commonwealth Equity Services LLC now owns 123,459 shares of the biotechnology company’s stock valued at $1,255,000 after acquiring an additional 5,004 shares in the last quarter. Finally, Avidian Wealth Solutions LLC acquired a new position in BioCryst Pharmaceuticals in the 1st quarter valued at approximately $305,000. 58.33% of the stock is currently owned by institutional investors.

NASDAQ:BCRX traded down $0.02 on Thursday, reaching $15.37. 1,854,651 shares of the company’s stock were exchanged, compared to its average volume of 4,598,104. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of -12.81 and a beta of 2.59. BioCryst Pharmaceuticals has a 52-week low of $3.30 and a 52-week high of $18.48. The business has a fifty day moving average of $15.81 and a 200-day moving average of $14.32.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Thursday, August 5th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.02). The firm had revenue of $49.96 million during the quarter, compared to analyst estimates of $31.37 million. BioCryst Pharmaceuticals had a negative net margin of 270.53% and a negative return on equity of 5,272.40%. As a group, research analysts anticipate that BioCryst Pharmaceuticals will post -1.22 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a commercial-stage biotechnology company, which engages in the development and discovery of novel, oral, and small-molecule medicines. It focuses on the oral treatments for rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease.

Further Reading: Why is cost of goods sold important?

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.